MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock from...
$16,432K
Proceeds from the
exercise of stock options
$17K
(-70.18%↓ Y/Y)
Net cash provided by
financing activities
$16,510K
(-25.83%↓ Y/Y)
Net increase in cash
and cash...
$8,341K
(153.06%↑ Y/Y)
Canceled cashflow
$8,169K
Accrued expenses
$1,465K
(144.27%↑ Y/Y)
Stock-based compensation
$935K
(-23.80%↓ Y/Y)
Accounts payable
$627K
(-77.82%↓ Y/Y)
Amortization of right-of-use
assets, operating...
$247K
(-45.47%↓ Y/Y)
Other long-term
prepaid assets
-$170K
Amortization of debt discount
$60K
(71.43%↑ Y/Y)
Depreciation
$36K
(-64.00%↓ Y/Y)
Net cash used in
operating activities
-$8,165K
(57.18%↑ Y/Y)
Effect of foreign
currency on cash and cash...
-$4K
(-103.81%↓ Y/Y)
Canceled cashflow
$3,540K
Net loss
-$8,217K
(62.26%↑ Y/Y)
Change in fair value of
warrant liabilities
-$2,483K
(-281.77%↓ Y/Y)
Prepaid expenses and
other current assets
$753K
(154.29%↑ Y/Y)
Operating lease
liabilities
-$252K
(42.86%↑ Y/Y)
Back
Back
Cash Flow
Elicio Therapeutics, Inc. (ELTX)
Elicio Therapeutics, Inc. (ELTX)
source: myfinsight.com